We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
DnB Asset Management
176
DnB Asset Management
Norway
$2.9M +$198K +5,466 +7%
VC
177
Vestor Capital
Illinois
$2.9M +$2.77M +76,478 +1,357%
Cerity Partners
178
Cerity Partners
New York
$2.86M -$2.74M -75,555 -48%
SF
179
Synovus Financial
Georgia
$2.84M -$48.4K -1,337 -2%
QC
180
Quantessence Capital
New York
$2.84M +$2.92M +80,558 New
QT
181
Quantbot Technologies
New York
$2.82M +$2.89M +79,961 New
CFM
182
Catalyst Funds Management
Australia
$2.79M +$1.73M +47,837 +153%
OAM
183
Ostrum Asset Management
France
$2.78M +$331K +9,154 +13%
UIM
184
USS Investment Management
United Kingdom
$2.71M -$42.1K -1,163 -1%
FAM
185
Fred Alger Management
New York
$2.69M -$1.43M -39,493 -34%
CUAMC
186
China Universal Asset Management Company
China
$2.67M -$321K -8,856 -10%
Cetera Investment Advisers
187
Cetera Investment Advisers
Illinois
$2.56M +$2.29M +63,227 +667%
UIC
188
Uniplan Investment Counsel
Wisconsin
$2.53M +$425K +11,749 +20%
KA
189
Kearns & Associates
California
$2.5M – – –
AG
190
AlTi Global
New York
$2.48M -$708K -19,544 -22%
MSV
191
MN Services Vermogensbeheer
Netherlands
$2.36M – – –
FAF
192
Första AP-fonden
Sweden
$2.32M +$253K +7,000 +12%
MGP
193
Metis Global Partners
California
$2.3M -$95.7K -2,644 -4%
MIF
194
Mediolanum International Funds
Ireland
$2.21M +$242K +6,697 +12%
URS
195
Utah Retirement Systems
Utah
$2.21M -$60.5K -1,671 -3%
PFSRSONJ
196
Police & Firemen's Retirement System of New Jersey
New Jersey
$2.2M +$111K +3,063 +5%
BPAMU
197
BTG Pactual Asset Management US
New York
$2.16M +$2.21M +61,131 New
CI Investments Inc
198
CI Investments Inc
Ontario, Canada
$2.11M +$214K +5,918 +11%
Creative Planning
199
Creative Planning
Kansas
$2.11M +$265K +7,318 +14%
SC
200
Searle & Co
Connecticut
$2.03M – – –
6 7
8
9 10

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.